Figure 6

Serum IL-1β Decreases with hMSC Treatment. Cardiac puncture was done to obtain adequate serum samples from mice with and without treatment with hMSCs. The acute asthma mice had significantly elevated levels of systemic IL-1β (6A, n = 8, p < 0.001). Systemic IL-1β concentrations were altered by hMSCs in the acute asthma model when hMSCs were given three days after challenge (peak inflammation). hMSCs significantly decreased the level of systemic IL-1β (n = 2, p = 0.05). Systemic IFNγ concentrations were increased in the acute asthma mice after hMSC treatment (6B, n = 4, p = 0.043). This was dependent on the presence of in vivo inflammation, since saline animals given hMSCs had no detectable serum IFNγ.